Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2013

View Archived Issues

Small-molecule lipid II inhibitors identified as potential antibacterials

NDC-1308, a novel compound inducing remyelination and slowing clinical signs in EAE mice

S. pneumoniae whole-cell vaccine undergoes phase I study

Alkermes completes enrollment in pivotal study of aripiprazole lauroxil

Three clinical studies of Parkinson's disease candidate opicapone reported

WISP1 gene expression linked to adipose tissue differentiation and obesity

Gicare Pharma develops compounds for visceral pain

Novel PCSK9 expression inhibitors described in Kowa patent

U.S. researchers design prodrugs of riluzole

Mileutis divulges peptides for lactation disorders

Sysmex Inostics and Bayer HealthCare to develop blood-based companion diagnostic tests

Molecular Templates raises funds to advance MT-3724

The Medicines Company and Alnylam to advance ALN-PCSsc

Ariad Pharmaceuticals gives update on Iclusig development

Immunogenicity and efficacy of HIVAX vaccine: results of a first-in-human study

CGEN-15001 is effective in an animal model of type 1 diabetes

FDA accepts filing for Bunavail NDA

Promedior begins phase II study of PRM-151 in myelofibrosis

Phase I/II study of Portola Pharmaceuticals' dual SYK/JAK inhibitor commences

QRxPharma meets with the FDA regarding MoxDuo NDA

Novogen acquires new technology targeting the Tm5NM1 protein

Phase III bivalirudin trial enrolls first patient

Kowa seeks approval in Japan for K-115

Morphotek reports initiation of phase I study of MORAb-004 in pediatric patients

Positive risk-benefit leads Gilead to end phase III study of idelalisib early

Nycomed to return worldwide rights to veltuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...